LSIMF is a DSIT non-dilutive capital grant programme funding pharmaceutical and medical-device manufacturing in the UK. In April 2026 it distributed over £80m to four sites: Accord Healthcare in Barnstaple (£45m+), University of Birmingham (£10m), Codis in Haverhill, and Norgine in Hengoed.Source: DSIT / Lowdown

How much did Accord Healthcare receive from LSIMF in 2026?

Accord Healthcare's Barnstaple site received over £45m from LSIMF on 14 April 2026, the largest single award in the round. Accord supplies roughly 9% of NHS prescriptions by volume.Source: DSIT / Lowdown

Why is UK life sciences investment being directed outside London and Oxford?

DSIT has an explicit geographic mandate to steer LSIMF capex beyond the Golden Triangle of London, Oxford, and Cambridge. The April 2026 round funded sites in Devon, the Midlands, Suffolk, and South Wales.Source: DSIT / Lowdown

Background

DSIT's Life Sciences Innovative Manufacturing Fund allocated over £80m to four regional sites on 14 April 2026: Accord Healthcare in Barnstaple received over £45m (the manufacturer supplies roughly 9% of NHS prescriptions by volume); the University of Birmingham's Precision Health Technologies Accelerator received £10m for cell, gene, and mRNA work; Codis in Haverhill received funding for spray-drying capacity serving cancer and neurodegenerative therapies (29 jobs); and Norgine in Hengoed received over £20m . None of the four sites sits within the Oxford-Cambridge-London triangle.

LSIMF is a capital grant programme operating within the Life Sciences Vision framework. Awards are non-dilutive capital grants, making them attractive to both large generic-medicine producers (Accord Healthcare is owned by Intas Pharmaceuticals) and university commercialisation bodies. The geographic mandate is explicit: DSIT is deliberately steering capex beyond the Golden Triangle to Devon, the Midlands, Suffolk, and South Wales. That signals a policy conviction that life-sciences manufacturing anchor points are a better regional-development instrument than conventional grant schemes.

This £80m allocation lifts cumulative UK life sciences investment in 2026 to £600m; DSIT is targeting £1bn by summer, implying roughly £400m still to be announced before July. The fund sits alongside the British Business Bank's direct-investment mandate and the Sovereign AI Unit as part of a broader state-capital deployment strategy, but its distinguishing feature is the focus on physical manufacturing rather than software or compute infrastructure.